Comparison of Efficacy and Safety of Metvixia® Natural Daylight Photodynamic Therapy Versus Conventional Metvixia® Photodynamic Therapy in patients With grade I and II actinic keratosis of the scalp: a phase III trial - Metvix®, Natural Daylight Photodynamic Therapy, Actinic keratosis

CHU de Limoges0 个研究点目标入组 26 人开始时间: 2015年6月22日最近更新: 2018年11月19日

适应症

试验速览

暂无简介。

•Clinical diagnosis of at least 10 previously untreated AK lesions of Grade 1 and/or 2 of the scalp (at least 5 KA at each hlf of the scalp)
•Males or females above 18 years of age.
•Written informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 11
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 15

•- Patients with porphyria.
•-Known allergy to metvixia® compound or excipients of the cream.
•-Patients with history of hypersensitivity to nut products
•-Patients receiving local treatment in the scalp areaea within the last 30 days.
•-Patients receiving topical treatment,chemotherapy or immunotherapy in scalp area within the last 2 months.
•-Sclerodermiform / nodular basal cell/intraepithelial carcinoma in the treated area
•-Pregnant or breast-feeding women

发起方

CHU de Limoges